Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Met1-Ser301 HEK-293 Gal Cer micro-globulin
- Product Overview:
CD1d is a lipid antigen-presenting molecule and a member of the group II CD1 family expressed by humans and mice.{60764} It is composed of a heavy chain, a transmembrane region, and a short intracellular C-terminal tail.{60764} The heavy chain contains three extracellular domains that associate with the light-chain β2-microglobulin. It is expressed primarily by antigen-presenting cells.{60764,60765} CD1d is directly involved in the process of presenting lipid antigens to T cells and invariant natural killer T (iNKT) cells to induce an immune response, including the secretion of specific cytokines depending on the antigen presented. Activation of iNKT cells by CD1d presentation of α-galactosylceramide (α-GalCer) in a murine model of melanoma reduces the number of metastases, but only when bone marrow-derived dendritic cells (BMDCs) were used to prolong iNKT cell responses.{60766} Cayman’s CD1d Extracellular Domain/B2M Heterodimer (human, recombinant) protein consists of 393 amino acids and has a calculated molecular weight of 45 kDa (33.3 (CD1d) + 11.7 (B2M) kDa). By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 55.7 kDa (43.2 (CD1d) + 12.5 (B2M) kDa) due to glycosylation.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.